Related Experiment Video
Updated: Dec 22, 2025
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
GGP modified daunorubicin plus dioscin liposomes inhibit breast cancer by suppressing epithelial-mesenchymal
Xue-Min Yao1, Feng-Ju Niu2, Liang Kong1
1School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China.
Abstract:
Tumor invasion and metastasis are the nodus of anti-tumor. Epithelial cell-mesenchymal transition is widely regarded as one of the key steps in the invasion and metastasis of breast cancer. In this study, GGP modified daunorubicin plus dioscin liposomes are constructed and characterized. GGP modified daunorubicin plus dioscin liposome has suitable particle size, narrow PDI, zeta potential of about -5 mV, long cycle effect, and enhanced cell uptake due to surface modification of GGP making the liposome could enter the inside of the tumor to fully exert its anti-tumor effect. The results of in vitro experiments show that the liposome has superior killing effect on tumor cells and invasion. In vivo results indicate that the liposome prolongs the drug's prolonged time in the body and accumulates at the tumor site with little systemic toxicity. In short, the targeted liposome can effectively inhibit tumor invasion and may provide a new strategy for the treatment of invasive breast cancer.
Insights
This study developed targeted liposomes to treat invasive breast cancer. The novel GGP-modified liposomes effectively inhibit tumor invasion and metastasis with reduced systemic toxicity, offering a promising new therapeutic strategy.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery
Background:
- Tumor invasion and metastasis are critical challenges in anti-cancer therapy.
- Epithelial-mesenchymal transition (EMT) is a key process in breast cancer invasion and metastasis.
Purpose of the Study:
- To construct and characterize GGP-modified daunorubicin plus dioscin liposomes for enhanced anti-cancer effects.
- To evaluate the efficacy of these targeted liposomes against invasive breast cancer.
Main Methods:
- Liposomes were modified with GGP for enhanced tumor targeting.
- In vitro cytotoxicity and invasion assays were performed.
- In vivo studies assessed drug circulation time, tumor accumulation, and systemic toxicity.
Main Results:
- GGP-modified liposomes exhibited optimal particle size, narrow PDI, and suitable zeta potential.
- Enhanced cellular uptake and superior in vitro killing of tumor cells were observed.
- In vivo studies demonstrated prolonged drug circulation, significant tumor accumulation, and minimal systemic toxicity.
Conclusions:
- GGP-modified daunorubicin plus dioscin liposomes effectively inhibit tumor invasion and metastasis.
- This targeted liposomal formulation represents a promising new strategy for invasive breast cancer treatment.
